📈 Jumpstart Signal Watchlist — October 28, 2026

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $14.65 is 4% below 3yr high $15.26 · ⏳ SMA200 $10.81 (current price $14.65 is above) · 💰 Market Cap $990M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 327% (>20%); ROE 24% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.06 (<1.5).
⏰ Entry (E): 9/20
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×1).
✅ Bioventus Inc. (NASDAQ:BVS) Stock Has Average Target Price of $16.80 — MarketBeat.
🤖 The article reports that six analysts rate Bioventus a Buy, with an average 12-month price target of $16.80. It also notes a recent Weiss Ratings upgrade to Buy, though some of the other analyst actions and financial results it discusses predate the four-week window.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: Avantor supplies laboratory products, high-purity materials, and services to life sciences, biopharma, healthcare, and advanced-technology companies. Its offerings support scientific research and production, including biopharmaceutical manufacturing.
- 🎯 Current $16.69 is 40% below 3yr high $27.70 · ⏳ SMA200 $11.24 (current price $16.69 is above) · 💰 Market Cap $11.4B
- AVTR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (9.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 129% (>20%); Low LT D/E 0.63 (<1.0); PEG ratio 0.26 (<1.5).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Avantor® Reports Third Quarter 2026 Results — PR Newswire.
🤖 Avantor reported third-quarter sales growth of 4.6% and organic growth of 5.2%, with revenue and adjusted EPS exceeding management’s expectations. The company also raised its full-year organic revenue growth, adjusted EPS, and free cash flow guidance.
✅ Avantor (AVTR) is Regaining Market Confidence — Yahoo Finance.
🤖 The article describes improving investor confidence amid a strong third-quarter share-price gain, a return to organic growth in VWR, and improving Bioprocessing orders. It also notes that the author trimmed their position as the stock approached their valuation.
⚪️ Avantor appoints new Chief Information Officer — Yahoo Finance.
🤖 Avantor named Mikey Santiago as CIO to lead its global IT strategy and digital transformation. The appointment may support operational priorities, but the article does not report a direct financial or business catalyst.
🍭 Bonus (B): 0/10 — Laboratory Analytical Instruments

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $11.93 is 6% below 3yr high $12.66 · ⏳ SMA200 $9.40 (current price $11.93 is above) · 💰 Market Cap $2.0B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 4/20
- 🔔 Strong above EMA21 (9.1%)
- 🔔 Strong above EMA50 (11.6%)
- 📈 RSI at 62 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×3 ⚪️×1; showing 3 of 4).
✅ Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors — Business Wire.
🤖 Vir appointed Suzanne Topalian, a prominent cancer immunotherapy expert, to its board. Her experience is relevant to the company’s oncology strategy, though the appointment itself does not change financial guidance.
✅ Vir, Gilead team up on solid tumor cancer therapies in up to ... — Reuters.
🤖 Vir and Gilead agreed to discover and develop three solid-tumor cancer candidates, with Vir eligible for $90 million upfront, near-term milestones, and up to $1.74 billion in additional payments plus royalties. The deal adds substantial potential funding and commercial upside.
⚪️ Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer — Business Wire.
🤖 Vir announced Aziz Sawaf’s appointment as CFO, effective October 5. The article reports a leadership change but no accompanying financial or strategic update.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Red Violet, Inc. provides identity intelligence software and data solutions for identity verification, fraud detection and prevention, risk mitigation, investigations, due diligence, customer acquisition, and asset recovery. Its products include idiCORE and FOREWARN.
- 🎯 At/above 3yr high $82.40 (current $82.40) · ⏳ SMA200 $56.83 (current price $82.40 is above) · 💰 Market Cap $1.2B
- RDVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (13.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 89% (>20%); Revenue growth 23% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 4/20
- 📈 RSI at 62 showing strength
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×3 ❌×1 ⚪️×1; showing 4 of 5).
✅ red violet Climbs 25 Spots to No. 82 on TIME's America's Growth Leaders of 2027 List — GlobeNewswire.
🤖 Red Violet rose from No. 107 to No. 82 on TIME’s growth-leaders list, offering favorable recognition of the company’s growth. The article was published October 27, 2026.
✅ Red Violet Inc stock hits all-time high at 82.1 USD — Investing.com.
🤖 The article reports RDVT reaching an all-time high and highlights previously reported earnings that beat expectations, 23% year-over-year revenue growth, and positive analyst coverage. These factors support a favorable view, though the earnings and coverage details are not new results in this article.
❌ Red Violet (NASDAQ:RDVT) Stock Rating Lowered by Zacks Research — MarketBeat.
🤖 Zacks Research downgraded RDVT from Strong Buy to Hold, a negative analyst-rating change. The article notes that the broader analyst consensus remains positive.
⚪️ Red Violet (NASDAQ:RDVT) Sets New 1-Year High - Here's What Happened — MarketBeat.
🤖 The article reports that RDVT reached a new one-year high and recaps mixed analyst actions, including a Zacks downgrade to Hold and a Weiss upgrade. The price milestone is backward-looking, so the article does not establish a clear new directional catalyst.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: CareDx, Inc. is a precision medicine company focused on transplant patients. It develops diagnostics, digital health tools, lab products, and patient support services to help monitor care before and after organ transplantation.
- 🎯 At/above 3yr high $72.13 (current $72.13) · ⏳ SMA200 $33.01 (current price $72.13 is above) · 💰 Market Cap $3.7B
- CDNA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 59/60
- 🏦 Low drawdown (12.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1394% (>20%); Revenue growth 52% (>15%); ROE 26% (>15%).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (8.9%)
- 🔔 Strong above EMA50 (21.9%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 69 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×4; showing 3 of 4).
✅ BTIG raises CareDx stock price target to $81 on revenue outlook — Investing.com.
🤖 BTIG raised its price target to $81 from $74 and maintained a Buy rating, citing CareDx’s revenue outlook. The higher target and continued Buy rating are positive analyst signals.
✅ CareDx (CDNA) After Kidney Week Data Is The Story Already Priced In — Yahoo Finance.
🤖 The article discusses new AlloSure Kidney data presented at ASN Kidney Week, including findings relevant to transplant monitoring and clinical decision-making. The data may support the product’s clinical value, though the headline questions whether the news is already reflected in the share price.
✅ CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026 — Business Wire.
🤖 CareDx highlighted data associating elevated AlloSure Kidney results with nearly three times the risk of adverse graft outcomes in certain patients. The findings may strengthen the test’s clinical relevance and support adoption.
🍭 Bonus (B): 0/10 — Medical Laboratories

🏢 What they do: Karat Packaging Inc. manufactures and distributes disposable foodservice products used by restaurants and other foodservice businesses. Its products include food and take-out containers, cups, lids, cutlery, straws, tableware, bags, and compostable packaging, along with related supplies and services.
- 🎯 Current $53.40 is 2% below 3yr high $54.68 · ⏳ SMA200 $35.33 (current price $53.40 is above) · 💰 Market Cap $1.1B
- KRT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (13.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 170% (>20%); ROE 30% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 📈 RSI at 53 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×3).
✅ Karat Packaging stock hits all-time high at 55.38 USD — Investing.com.
🤖 Karat Packaging shares reached a reported all-time high, reflecting strong recent share-price performance. The article also notes that second-quarter earnings per share beat expectations, though revenue was slightly below one analyst forecast.
✅ Should Karat Packaging’s Online-Driven Earnings Beat Require Action From Karat Packaging (KRT) Investors? — Yahoo Finance.
🤖 The article highlights record quarterly sales and results that exceeded analyst expectations, with customer demand and online growth cited as drivers. It also notes that the strong results may raise expectations and that valuation and online growth are risks to watch.
✅ Karat Packaging (NASDAQ:KRT) Reaches New 1-Year High — MarketBeat.
🤖 Karat Packaging shares reached a new 52-week high. The article also cites the company’s prior quarterly earnings beat and dividend increase, while noting that analyst ratings remain mixed.
🍭 Bonus (B): 0/10 — Rubber & Plastics Products

🏢 What they do: Best Buy Co., Inc. is a consumer electronics retailer that sells products such as computers, mobile phones, appliances, televisions, gaming equipment, and related accessories through its stores and online channels. It also provides technology services, including installation, repair, technical support, and product financing.
- 🎯 Current $96.96 is 6% below 3yr high $103.30 · ⏳ SMA200 $74.83 (current price $96.96 is above) · 💰 Market Cap $20.4B
- BBY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 70% (>20%); ROE 40% (>15%); Low LT D/E 0.37 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×3 ⚪️×2; showing 4 of 5).
✅ Best Buy Reveals Holiday Calendar With Doorbusters and Deals Throughout the Season — Yahoo Finance.
🤖 Best Buy outlined a schedule of holiday promotions, including weekly doorbusters and Black Friday deals. The promotions could support seasonal traffic and sales, though their effect on profitability is not reported.
✅ Meet Best Buy Gamers: A New Experience Built for Gamers — Business Wire.
🤖 Best Buy launched a beta gaming destination with personalized content, gear, offers, and sweepstakes. The initiative may help the retailer engage gaming customers and support sales in that category.
⚪️ Best Buy (BBY) In Focus Following IGN Deal As Valuation Debate Heats Up — Yahoo Finance.
🤖 The article discusses Best Buy’s gaming partnership and recent share-price gains, while noting a valuation estimate that suggests the stock may be overvalued. The potential business opportunity is balanced by valuation concerns.
⚪️ Best Buy Co., Inc. $BBY Stock Sold by Flagship Harbor Advisors LLC — MarketBeat.
🤖 The article centers on an institutional holding disclosure, which is a backward-looking filing rather than a directional catalyst. It also notes Best Buy’s consensus rating and price target.
🍭 Bonus (B): 0/10 — Radio, TV & Electronics Stores

🏢 What they do: GigaCloud Technology Inc. (GCT) operates a B2B e-commerce marketplace specializing in large-parcel merchandise like furniture, appliances, and fitness equipment. It provides an end-to-end platform that connects manufacturers (primarily in Asia) with retailers in markets such as the US and Europe, handling product sourcing, logistics, global fulfillment across 39 facilities, sales, and delivery.
- 🎯 At/above 3yr high $60.63 (current $60.63) · ⏳ SMA200 $43.90 (current price $60.63 is above) · 💰 Market Cap $565M
- GCT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 27% (>20%); Revenue growth 28% (>15%); ROE 29% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (5.5%)
- 🔔 Strong above EMA50 (12.4%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ GigaCloud Technology Inc Ranks Among Top 15 on Fortune’s Fastest Growing Companies™ 2026 and TIME’s America’s Growth Leaders 2027 Lists — GlobeNewswire.
🤖 GigaCloud announced it ranked No. 13 on Fortune’s fastest-growing companies list and No. 12 on TIME’s America’s Growth Leaders list. The recognition highlights its growth and financial performance, which may support investor confidence.
✅ GigaCloud Technology stock hits 52-week high at 58.27 USD — Investing.com.
🤖 The article reports that GCT reached a 52-week high and cites strong second-quarter results and a newly approved $120 million share repurchase plan. These developments point to positive momentum and shareholder returns.
✅ GigaCloud Technology (NASDAQ:GCT) Stock Lifted to “Strong Buy” by Wall Street Zen — MarketBeat.
🤖 Wall Street Zen upgraded GCT from “buy” to “strong buy,” with the article also noting that the company’s reported quarterly EPS and revenue exceeded consensus estimates. The rating change and earnings beat are favorable signals.
🍭 Bonus (B): 0/10 — Catalog & Mail-Order